The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.